The startup has developed an automated microtumor-based profiling technology for in vitro cancer diagnosis, enabling clinical institutions to evaluate the efficacy of various cancer drugs and combinations directly on patient-derived micro-tumors. This approach enhances treatment selection for physicians, ultimately improving patient outcomes in cancer management.
Funding
$3.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
KFounders
Product
Problem
Current methods for determining cancer drug efficacy rely on traditional 2D cell cultures or animal models, which often fail to accurately replicate the complex microenvironment of human tumors. This can lead to ineffective treatment selection and suboptimal patient outcomes. There is a need for more predictive and personalized approaches to cancer drug testing.
Solution
PreComb offers an automated microtumor-based profiling technology that utilizes patient-derived 3D tumor models to evaluate the efficacy of cancer drugs and combinations in vitro. The 3DTwin® platform replicates the real cancer microenvironment, enabling more accurate drug testing and improved prediction of patient response. By providing physicians with access to various drug options and personalized oncology insights, PreComb aims to enhance treatment selection, reduce side effects, and improve patient outcomes in cancer management. The platform facilitates high-throughput screening, standardized testing, and real-time imaging to accelerate drug discovery and translational cancer research.
Target Audience
PreComb's primary customers include pharmaceutical companies, clinical investigators, oncologists, and academic researchers seeking to improve cancer drug discovery, personalized treatment strategies, and patient outcomes.
Features
- Patient-derived 3D tumor models that replicate the complex tumor microenvironment
- Automated screening platform for standardized, reproducible drug testing
- High-throughput capabilities for testing multiple drugs and combinations simultaneously
- Real-time imaging and analysis of tumor response dynamics
- AI-guided data analysis and response prediction
- Customizable tumor models tailored to specific research needs
- Integration with clinical data for personalized oncology insights